Corcept Therapeutics (CORT), a specialty drug company that hasn’t generated revenue since 2009,...

|About: Corcept Therapeutics Incorp... (CORT)|By:, SA News Editor

Corcept Therapeutics (CORT), a specialty drug company that hasn’t generated revenue since 2009, wins FDA approval for its Korlym treatment that uses the active ingredient of the abortion pill RU-486 to treat Cushing’s Syndrome. Shares +42.5% after a trading halt.